PE20160864A1 - Espiro-oxazolonas - Google Patents

Espiro-oxazolonas

Info

Publication number
PE20160864A1
PE20160864A1 PE2016000722A PE2016000722A PE20160864A1 PE 20160864 A1 PE20160864 A1 PE 20160864A1 PE 2016000722 A PE2016000722 A PE 2016000722A PE 2016000722 A PE2016000722 A PE 2016000722A PE 20160864 A1 PE20160864 A1 PE 20160864A1
Authority
PE
Peru
Prior art keywords
spiro
oxazolones
indeno
oxazol
benzofuran
Prior art date
Application number
PE2016000722A
Other languages
English (en)
Inventor
Cosimo Dolente
Patrick Schnider
Valerie Runtz-Schmitt
Bernhard Fasching
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20160864A1 publication Critical patent/PE20160864A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a derivados de espiro-oxazolonas de formula I donde X1, X2, X3 y X4 son C-R1 o N; R1 es hidrogeno, halogeno, entre otros; R2 y R3 son H o alcoxi C1-C6 o R2 y R3 son =O; Y1, Y2, Y3 y Y4 son C-R4 o N; R4 es hidrogeno, halogeno, entre otros; m es 1, 2 o 3; n es 0 o 1. Son compuestos preferidos: (1R)-2´-(1´H,3H-espiro[2-benzofuran-1,4´-piperidin]-1´-il)-2,3-dihidro-4´H-espiro[indeno-1,5´-[1,3]oxazol-4´-ona; (1S)-2´-(1´H,3H-espiro[2-benzofuran-1,4´-piperidin]-1´-il)-2,3-dihidro-4´H-espiro[indeno-1,5´-[1,3]oxazol-4´-ona; entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos actuan antagonistas del receptor V1a, siendo utiles en el tratamiento de secrecion inadecuada de vasopresina, ansiedad, trastornos depresivos, trastornos del espectro autista, esquizofrenia, entre otros.
PE2016000722A 2013-12-19 2014-12-16 Espiro-oxazolonas PE20160864A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13198604 2013-12-19

Publications (1)

Publication Number Publication Date
PE20160864A1 true PE20160864A1 (es) 2016-09-03

Family

ID=49876427

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000722A PE20160864A1 (es) 2013-12-19 2014-12-16 Espiro-oxazolonas

Country Status (35)

Country Link
US (3) US10479796B2 (es)
EP (1) EP3083633B1 (es)
JP (1) JP6530407B2 (es)
KR (1) KR102353431B1 (es)
CN (1) CN105814062B (es)
AR (1) AR098783A1 (es)
AU (1) AU2014364729B2 (es)
BR (1) BR112016013058B1 (es)
CA (1) CA2932063C (es)
CL (1) CL2016001495A1 (es)
CR (1) CR20160215A (es)
DK (1) DK3083633T3 (es)
EA (1) EA029167B1 (es)
ES (1) ES2657994T3 (es)
HK (1) HK1223920A1 (es)
HR (1) HRP20180160T1 (es)
HU (1) HUE036203T2 (es)
IL (1) IL245464B (es)
LT (1) LT3083633T (es)
MA (1) MA39139B1 (es)
MX (1) MX370663B (es)
MY (1) MY177313A (es)
NO (1) NO3083633T3 (es)
NZ (1) NZ719765A (es)
PE (1) PE20160864A1 (es)
PH (1) PH12016500919B1 (es)
PL (1) PL3083633T3 (es)
PT (1) PT3083633T (es)
RS (1) RS56791B1 (es)
SG (1) SG11201604915PA (es)
SI (1) SI3083633T1 (es)
TW (1) TWI548639B (es)
UA (1) UA117273C2 (es)
WO (1) WO2015091411A1 (es)
ZA (1) ZA201603221B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201600522A (zh) * 2014-02-20 2016-01-01 赫孚孟拉羅股份公司 螺-唑酮
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
AR127706A1 (es) 2021-11-19 2024-02-21 Hoffmann La Roche Síntesis de 2’-(7,7-dimetil-1’h,7h-espiro[furo[3,4-b]piridin-5,4’-piperidin]-1’-il)-1,3-dihidro-4’h-espiro[inden-2,5’-[1,3]oxazol]-4’-ona

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365079B2 (en) * 2002-11-29 2008-04-29 Banyu Pharmaceutical Co., Ltd. Azole derivatives
US7351706B2 (en) 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
MX2009005507A (es) * 2006-12-07 2009-06-03 Hoffmann La Roche Derivados de espiro-piperidina.
RU2009123134A (ru) * 2006-12-22 2011-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные спиро-пиперидина
ATE536356T1 (de) * 2007-01-12 2011-12-15 Hoffmann La Roche Spiropiperidin-glycinamid-derivate
KR101348499B1 (ko) * 2008-11-13 2014-01-06 에프. 호프만-라 로슈 아게 스피로-5,6-다이하이드로-4h-2,3,5,10b-테트라아자-벤조〔e〕아줄렌

Also Published As

Publication number Publication date
ES2657994T3 (es) 2018-03-07
HUE036203T2 (hu) 2018-06-28
AR098783A1 (es) 2016-06-15
PL3083633T3 (pl) 2018-04-30
SI3083633T1 (en) 2018-02-28
DK3083633T3 (da) 2018-01-29
EP3083633B1 (en) 2017-11-29
ZA201603221B (en) 2022-05-25
HK1223920A1 (zh) 2017-08-11
MY177313A (en) 2020-09-11
US20170008901A1 (en) 2017-01-12
NO3083633T3 (es) 2018-04-28
KR102353431B1 (ko) 2022-01-20
US20200039997A1 (en) 2020-02-06
MA39139A1 (fr) 2018-05-31
CN105814062B (zh) 2018-04-24
US11578077B2 (en) 2023-02-14
JP2017502028A (ja) 2017-01-19
CN105814062A (zh) 2016-07-27
UA117273C2 (uk) 2018-07-10
TWI548639B (zh) 2016-09-11
US10479796B2 (en) 2019-11-19
JP6530407B2 (ja) 2019-06-12
KR20160098490A (ko) 2016-08-18
PH12016500919A1 (en) 2016-06-27
CL2016001495A1 (es) 2016-12-16
AU2014364729A1 (en) 2016-05-26
EA201691189A1 (ru) 2016-10-31
MX2016007809A (es) 2016-09-07
CA2932063C (en) 2023-03-07
MA39139B1 (fr) 2019-01-31
NZ719765A (en) 2022-04-29
AU2014364729B2 (en) 2018-11-22
BR112016013058B1 (pt) 2021-02-23
PH12016500919B1 (en) 2016-06-27
IL245464A0 (en) 2016-06-30
SG11201604915PA (en) 2016-07-28
HRP20180160T1 (hr) 2018-02-23
IL245464B (en) 2019-10-31
WO2015091411A1 (en) 2015-06-25
US20230106150A1 (en) 2023-04-06
RS56791B1 (sr) 2018-04-30
EA029167B1 (ru) 2018-02-28
EP3083633A1 (en) 2016-10-26
CR20160215A (es) 2016-07-15
MX370663B (es) 2019-12-19
TW201536790A (zh) 2015-10-01
PT3083633T (pt) 2018-01-25
LT3083633T (lt) 2018-02-12
CA2932063A1 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
PE20170438A1 (es) Inhibidores espirociclicos de catepsina c
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20110296A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de orexina
AR074966A1 (es) Compuestos amino-heterociclicos
PE20150777A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
PE20090429A1 (es) Moduladores de gamma secretasa
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20170144A1 (es) 1h-pirrolo[2,3-c] piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h)-onas como inhibidores de proteinas bet
PE20161021A1 (es) Derivados heterociclicos biciclicos como inhibidores de bromodominio
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
DOP2009000232A (es) Metanoisoindoles y dionas de éstos como agentes anti-psicóticos.
PE20120418A1 (es) DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP)
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20150352A1 (es) Moduladores del receptor de glucocorticoides de azadecalina fusionada de heteroaril-cetona
NI201300043A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
AR064547A1 (es) Derivados de azaspiro como antagonistas del receptor v1a
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
PE20100718A1 (es) Derivados triciclicos de 1, 4-dihidropiridina [b, e]-condensados como inhibidores de aurora quinasas
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
PE20160864A1 (es) Espiro-oxazolonas
PE20150943A1 (es) 2-oxo-2,3-dihidro-indoles para el tratamiento de desordenes de cns
PE20170427A1 (es) Peptidos como agonistas de la oxitocina